ZYBERNO
Stock Report
Updated Aug 30, 2026

Cogent Biosciences, Inc. (COGT)

Healthcare • NASDAQ

$34.67

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
Cogent Biosciences, Inc. (COGT) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-72.6%)
Debt-to-Equity (Solvency Risk):GOOD (0.47x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-50.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Cogent Biosciences, Inc. (COGT) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, COGT generated -$286.13M in Owner Earnings. Capital was deployed as follows: $1.46M invested in capital expenditures. Reinvestment rate: 0.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:34.67
Market Cap:$5.93B

Valuation Multiples (2)

P/B Ratio:11.14x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$5.97B

Price Action & Momentum (1)

% of 52-Week High:79.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-48.7%
Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-0.2%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$6.23
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-750.0%
Latest Earnings Filed:2026-08-10
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:13.57x
Quick Ratio:13.57x
Cash Ratio:3.06x

Leverage Analysis (3)

Debt To Equity Ttm:0.47x
Debt-to-Equity Ratio:0.47x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-79.32x
Times Interest Earned:-79.32

Capital Structure (4)

Working Capital:745,524,000.00
Cash And Cash Equivalents:181,172,000.00
Long Term Debt:$223.46M
Net Debt:$43.77M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$389.09M

Bottom Line Performance (3)

-$377.18M
Income Before Tax:$0.00
Ebitda Ttm:-386,507,000.00

Operating Expenses (5)

Operating Expenses:389,093,000.00
R And D Expense:290,724,000.00
Sga Expense:98,369,000.00
Income Tax Expense:$0.00
Interest Expense:4,203,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$834.55M
Current Assets:$804.82M
Ppe Net:4,775,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:302,158,000.00
Current Liabilities:59,296,000.00
Long Term Debt:$223.46M
Short Term Debt:$1.49M

Equity & Capital (3)

Equity:$532.39M
Retained Earnings:-$1.38B
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:7,488,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:17,107,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$284.82M-$286.27M

Investment Activities (2)

Investing Cash Flow:-$36.46M
Capital Expenditures Ttm:1,456,000.00

Financing Activities (3)

Financing Cash Flow:$52.54M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:25,000,000.00
Long Term Debt Issuance:$49.29M
Long Term Debt Repayments:$54.64M

Non-Cash Items (1)

Depreciation Amortization Ttm:2,586,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.16
-$2.16
Earnings Per Share Ttm:-$2.21

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.55

Book Value & Capital (2)

Book Value Per Share:$3.11
Cash Per Share:1.06

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$286.13M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-0.2%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):14.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:COGT
Company Name:Cogent Biosciences, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:171.01M
Shares Outstanding Basic:171.01M
Shares Outstanding Diluted:171.01M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 03:41:36 UTC
Data Timestamp:2026-08-30T03:41:36.941647
Scroll to Top